Skip menus, go to main page content

To Our Shareholders
and Investors

Top
To Our Shareholders and Investors

IR News

November 13, 2026

Management & Finance

Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2026
October 29, 2026

R & D

Nippon Shinyaku Enters into Exclusive Sublicense Agreement with Tanabe Pharma to Commercialize loncastuximab tesirine-lpyl (MT-2111) for Relapsed or Refractory Diffuse Large B-cell Lymphoma in Japan
October 01, 2026

R & D

Five-Year Clinical Trial Data for Brogidirsen (NS-089/NCNP-02), an Investigational Treatment for Duchenne Muscular Dystrophy, Presented at the World Muscle Society 2026 Congress
August 26, 2026

R & D

SAKIGAKE Pharmaceutical Product (Pioneering Drug) Designation Granted to NS-035 for the Treatment of Fukuyama Congenital Muscular Dystrophy

Upcoming Events

November 13, 2026
FY2026 2nd Qtr results announcement and IR meeting
August 06, 2026
FY2026 1st Qtr results announcement and IR meeting
May 15, 2026
Annual results announcement and IR meeting （Q4/FY2025）
March 02, 2026
R&D Meeting
February 09, 2026
IR Meeting (Q3/FY2025)

Financial/Capital Strategy

Management Policy and Plan

Business/Financial Information

IR Library

Sustainability Management

Stock and Shareholder Information

To Our Individual Investors

IR e-mail

Subscribe (only 1 minute required) to receive the latest news by e-mail.

Most Viewed Pages

Oct 1-31, 2026

All Japanese Listed Companies' Website Ranking

Gomez
IR Site Ranking Silver 2025

Daiwa Investor Relations Co.Ltd. 2025 Internet IR Award

Related Link

Nippon Shinyaku’s DNA

Research & Development

Top
To Our Shareholders and Investors